A Randomized, Phase 3, open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Platinum-Based Doublet Chemotherapy, and Ipilimumab (ANTI-CTLA-4 Antibody), Versus Pembrolizumab Monotherapy in First-line treatment of patients with Advanced or metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 equals to or greater than 50%
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%
“An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC) “
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
A Phase 1b Study of LY2835219 in Combination with Multiple Single-Agent Options for Patients with Stage IV NSCLC
A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen
Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
